Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here

Request a Proposal  

News

Pharm-olam is a global clinical research organization that delivers right-sized trial services to pharmaceutical, biotechnology, government, and public health organizations around the world.

Blog Feature

By: Pharm-Olam
April 3rd, 2019

Houston, April 3rd, 2019 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology, infectious diseases and vaccines, and rare and orphan diseases, has been named a winner in Life Science Leader magazine’s 2019 CRO Leadership Awards. Pharm-Olam was rated highly by small pharma survey respondents, as well as all survey respondents combined, for delivering excellent clinical research services in Compatibility, Quality, and Reliability core award categories.               

Blog Feature

By: Pharm-Olam
March 6th, 2019

Houston, March 6, 2019 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology-hematology, infectious diseases and vaccines, and rare diseases, is marking its 25th anniversary with several announcements. These include an update to its rare disease service tier, progress on its transition to the Medidata Cloud platform, and ongoing global expansion. With record sales in 2018, these changes position Pharm-Olam for continued growth into 2019.  

GDPR_Checklist-cover

Join other Clinical Development experts to get the latest industry news, trends and insights.

As a thank you for subscribing, you'll receive a free copy of our GDPR Controller & Processor Checklist

Blog Feature

By: Pharm-Olam
February 5th, 2019

Houston, Feb. 5, 2019 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for rare and orphan diseases along with oncology, infectious diseases, and vaccines, is now enrolling patients in the U.S. and Europe into a pivotal Phase III study within the treatment of short bowel syndrome (SBS).

Blog Feature

Rare & Orphan Disease

By: Pharm-Olam
October 30th, 2018

Houston, Oct. 30, 2018 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology, infectious diseases and vaccines, and rare and orphan diseases, extends its congratulations to Ablynx, a Sanofi company, for its launch of Cablivi® (caplacizumab) in the German market for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Pharm-Olam is proud to have contributed to the execution and completion of its pivotal Phase III study.

Blog Feature

By: Pharm-Olam
October 24th, 2018

CRO accelerates the delivery of life-changing therapies with a single view of data for all clinical trial stakeholders

Blog Feature

By: John W Colby III
July 31st, 2018

Houston, July 31, 2018 – Pharm-Olam International, a global, full-service contract research organization (CRO) specializing in oncology, infectious diseases and vaccines, rare and orphan diseases, provides multiple resources for life science organizations to comply with the new European Union General Data Protection Regulation (GDPR). Pharm-Olam provides education and consultation on how the GDPR affects clinical trial conduct and also works directly with companies to achieve compliance.

Blog Feature

GDPR

By: Pharm-Olam
April 27th, 2018

HOUSTON, Tx. — April 26, 2018. Pharm-Olam International, a global, full-service Contract Research Organization (CRO) specializing in Oncology, Infectious Diseases & Vaccines, Rare Diseases and Pediatric indications, is prepared for the implementation of the European Union’s (EU’s) General Data Protection Regulation (GDPR), which will impact our industry among others where organizations collect and hold personal data on EU citizens.  Utilizing Pharm-Olam’s version of the Bow Tie Methodology for visual risk assessment and management, powered by Ideagen’s Q-Pulse software, Pharm-Olam is fully prepared for the global GDPR roll-out. In anticipation of GDPR’s effective date (May 25, 2018), Pharm-Olam will be hosting an interactive 60-minute live training webinar on May 15, 2018 at 11a.m. EST for its pharmaceutical and biotechnology partners and clients.  Registration and attendance is open to the public.  

Blog Feature

By: Admin
January 11th, 2018

Pharm-Olam International, a multinational, full-service Clinical Research Organization (CRO) specializing in Oncology, Infectious Diseases, Rare Diseases and Pediatric indications, today announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H. as Chief Medical Officer (CMO).